Patient dies in Sarepta gene therapy trial, adding to safety concerns
STATarrow_outwardSarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label
Sarepta Therapeuticsarrow_outwardSarepta Says Another Patient Died After Receiving Gene Therapy
Bloombergarrow_outwardSarepta shares tumble after report of patient death in early-stage trial - Investing.com Nigeria
Investing.com Nigeriaarrow_outwardSRPT INVESTOR DEADLINE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit โ Company Announcement - FT.com - Financial Times
Financial Timesarrow_outwardSarepta Therapeutics (SRPT) PT Raised to $28 at TD Cowen - StreetInsider
StreetInsiderarrow_outwardSarepta shares slump after report of patient death in early-stage study - TradingView
TradingViewarrow_outwardSarepta Therapeutics Stock (NASDAQ: SRPT) Swinging Wildly: What is The Latest - AskTraders.com
AskTraders.comarrow_outwardThird Death This Year Linked to Sarepta Therapeutics Gene Therapy Trials - geneonline.com
Geneonline.comarrow_outwardSarepta plunges after third patient death tied to gene therapy - report (SRPT:NASDAQ) - Seeking Alpha
Seeking Alphaarrow_outwardThird patient dies after receiving one of Sarepta's gene therapies - FirstWord Pharma
FirstWord Pharmaarrow_outwardSarepta patient dies in limb-girdle study, latest death after earlier safety concerns - Endpoints News
Endpoints Newsarrow_outwardSarepta to cut 36% of staff, add black-box warning to Elevidys - Healthcare Brew
Healthcare Brewarrow_outwardSRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
PR Newswirearrow_outwardThese Stocks Moved the Most Today: Lucid, TSMC, Elevance, Sarepta, PepsiCo, Abbott Labs, Archer Daniels, and More - Barron's
Barron'sarrow_outwardSarepta Therapeutics to cut 500 jobs amid restructuring - MSN
MSNarrow_outwardSarepta Soars 20% On 'Tough But Prudent' Move After Patient Deaths - Investor's Business Daily
Investor's Business Dailyarrow_outwardSarepta Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
GlobeNewswirearrow_outwardSarepta Slashes Staff, Maps Path Forward for Gene Therapy and Narrower Pipeline - MedCity News
MedCity Newsarrow_outwardLobbying Update: $260,000 of SAREPTA THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
Quiver Quantitativearrow_outwardRecon: BMS, Pfizer to sell Eliquis direct to patients at a discount; Sarepta to layoff 500 staff as it adds boxed warning for DMD gene therapy - Regulatory Affairs Professionals Society | RAPS
Regulatory Affairs Professionals Society | RAPSarrow_outwardSarepta Therapeutics' Reorganization Boosts Investor Confidence - Benzinga
Benzingaarrow_outwardSarepta shares soar on restructuring, R&D refocus - Proactive financial news
Proactive financial newsarrow_outwardSarepta's bold $400m pivot: Firm slashes workforce to secure financial future - BioXconomy
BioXconomyarrow_outwardSarepta leaps on strategic restructuring and pipeline prioritization - The Pharma Letter
The Pharma Letterarrow_outwardSarepta Therapeutics: What's Happening With SRPT Stock? - Forbes
Forbesarrow_outwardSarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales - insights.citeline.com
Insights.citeline.comarrow_outwardSarepta Slashes Workforce After Patient Deaths on Gene Therapy - Mint
Mintarrow_outwardSarepta Surges After-Hours As It Slashes 500 Jobs Amid FDA Black Box Warning For Gene Therapy โ Retail Eyes Rebound - Stocktwits
Stocktwitsarrow_outwardSarepta Stock Soars 30% Amid Restructuring and Shift to RNA-Based Treatments - AInvest
AInvestarrow_outwardSarepta to lay off about 500 employees after Duchenne gene therapy setbacks - BioPharma Dive
BioPharma Divearrow_outwardSarepta Axes 500, 36% of Workforce, in Restructuring after DMD Patient Deaths - Genetic Engineering and Biotechnology News
Genetic Engineering and Biotechnology Newsarrow_outwardSarepta Tags DMD Gene Therapy Elevidys With Black Box Warning, Axes 500 Staff - BioSpace
BioSpacearrow_outwardSarepta Therapeutics Stock Soars on Beleaguered Drugmaker's Restructuring Plan - Investopedia
Investopediaarrow_outwardStocks making the biggest moves after hours: United Airlines, Sarepta Therapeutics and more - CNBC
CNBCarrow_outwardSarepta Therapeutics Announces Strategic Restructuring Plan - TipRanks
TipRanksarrow_outwardSarepta to cut 36% of workforce amid strategic restructuring - Investing.com
Investing.comarrow_outwardMass. firm lays off 500 workers after gene therapy setback - NBC Boston
NBC Bostonarrow_outwardSarepta Therapeutics lays off 500 after gene therapy setback - The Business Journals
The Business Journalsarrow_outwardJPMorgan Cuts Sarepta (SRPT) PT, Keeps Overweight Rating - Insider Monkey
Insider Monkeyarrow_outwardDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - Morningstar
Morningstararrow_outwardSarepta Therapeutics Halts ELEVIDYS Shipments for Non-Ambulatory DMD Patients - Yahoo Finance
Yahoo Financearrow_outwardFDA investigates patient deaths after treatment with Sarepta's Duchenne gene therapy Elevidys - Fierce Pharma
Fierce Pharmaarrow_outwardFDA Announces Investigation of Deaths Following Treatment With Sareptaโs DMD Gene Therapy Elevidys - CGTLiveยฎ
CGTLiveยฎarrow_outwardFDA investigates patient deaths after treatment with Sarepta's gene therapy - Reuters
Reutersarrow_outward
Sarepta close
- 2025-07-18 18:40 event
- 45 sourceslanguage
- 100+ ads_click
- 1 week ago schedule